Sharif-Kashani Babak, Ghanbari Motlagh Ali, Mafi Ahmad R, Esnaashari Omid, Ramzi Mani, Taghizadeh Ali, Najafi Safa
Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tanaffos. 2019 Mar;18(3):244-253.
Venous thromboembolism (VTE) is one of the main causes of mortality in patients with cancer. This study was conducted to assess the incidence of deep vein thrombosis (DVT) in breast cancer patients receiving outpatient cancer therapy.
This multi-center prospective cohort study was conducted on patients with breast cancer, initiating an outpatient chemotherapy regimen in five medical centers in Iran. Eligible patients were enrolled in the study consecutively between January 2013 and January 2015. The primary outcome was lower extremity DVT based on duplex/doppler ultrasonography two months after the first course of chemotherapy (visit 2) and after the end of the course (visit 3). All patients were followed-up from the onset of chemotherapy until the first occurrence of lower extremity DVT, death, or the end of the course.
A total of 427 eligible breast cancer patients were recruited in the study, 403 of whom attended at least one follow-up visit. The mean (SD) duration of follow-up was 4 (1.3) months. During the follow-up, only one patient showed DVT on duplex/doppler ultrasonography in visit 2. Therefore, the two-month and overall cumulative incidence risk of DVT was 0.25% (95% CI: 0.00-0.74%). However, the mean D-dimer level showed no significant change (P>0.05).
Our findings showed the low risk of DVT in breast cancer patients receiving outpatient cancer therapy.
静脉血栓栓塞症（VTE）是癌症患者死亡的主要原因之一。本研究旨在评估接受门诊癌症治疗的乳腺癌患者深静脉血栓形成（DVT）的发生率。
这项多中心前瞻性队列研究针对在伊朗五个医疗中心开始门诊化疗方案的乳腺癌患者开展。符合条件的患者于2013年1月至2015年1月期间连续纳入研究。主要结局是在第一个化疗疗程后两个月（访视2）和疗程结束后（访视3）基于双功/多普勒超声检查的下肢DVT。所有患者从化疗开始直至首次发生下肢DVT、死亡或疗程结束均进行随访。
本研究共招募了427例符合条件的乳腺癌患者，其中403例至少参加了一次随访。随访的平均（标准差）时长为4（1.3）个月。在随访期间，仅1例患者在访视2的双功/多普勒超声检查中显示有DVT。因此，DVT的两个月及总体累积发病风险为0.25%（95%CI：0.00 - 0.74%）。然而，平均D - 二聚体水平无显著变化（P>0.05）。
我们的研究结果表明，接受门诊癌症治疗的乳腺癌患者发生DVT的风险较低。
